Download

Full Text

• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
• Lindström J., Ilanne-Parikka P., Peltonen M., et al., on behalf of the Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (2006) 1673-1679
• Li G., Zhang P., Wang J., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371 (2008) 1783-1789
• Kosaka K., Noda M., and Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67 (2005) 152-162
• Kawamori R., Tajima N., Iwamoto Y., et al., on behalf of the Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet (2009) 10.1016/S0140-6736(09)60222-1 published online April 22.
• Chiasson J.-L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., and for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
• Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V., and Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49 (2006) 289-297
• The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trials Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
• Anon. Actos Now for Prevention of Diabetes (ACT-NOW) (Feb 16, 2006). http://clinicaltrials.gov/ct2/show/NCT00220961 (accessed March 10, 2009).
• Scheen A.J. Pharmacological prevention of type 2 diabetes. In: Ekoe J.-M., Rewers M., Williams R., and Zimmet P. (Eds). The epidemiology of diabetes mellitus. 1st edn. (2008), Wiley-Blackwell, London 449-474
• Beals J.K. Pioglitazone reduces conversion from impaired glucose tolerance to type 2 diabetes. http://www.medscape.com/viewarticle/575860 (accessed March 30, 2009).
• Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
• Scheen A.J. Antidiabetic agents in patients with mild dysglycaemia: prevention or early treatment of type 2 diabetes?. Diabetes Metab 33 (2007) 3-12
• Scheen A.J. Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes?. Drugs 63 (2003) 933-951
• Chan J.C., Chan K.W., Ho L.L., et al., for the Asian Acarbose Study Group. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care 21 (1998) 1058-1061
• Nijpels G., Boorsma W., Dekker J.M., et al. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI). Diabetes Metab Res Rev 24 (2008) 611-616
• Zinman B., Harris S.B., Gerstein H.C., et al. Preventing type 2 diabetes using combination therapy: design and methods of the Canadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes Obes Metab 8 (2006) 531-537
• Bassler D., Montori V.M., Briel M., et al. Early stopping of randomized trials for overt efficacy is problematic. J Clin Epidemiol 61 (2008) 241-246